Hansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.

VEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase III trial.

H. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax (PXT002331) in Parkinson’s Disease.

Dunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and  improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.

Researchers from Sweden, Switzerland, France, Italy, and Germany report that expression of a post-stroke factor boost arterial plaque formation. The identification of the new target might open up an avenue to prevent embolism and further complications in stroke patients.

At the 11th Berlin Conference, Novo Holdings outlined details of a new €135m investment fund launched to push the development of new drug classes urgently needed to fight antimicrobial resistance. European Biotechnology editors were the first to talk with Aleks Engel, Partner at Novo Holdings, and George Griffin, Chair of the Repair Impact Fund’s Scientific Advisory Board, about the construction and the goal of the fund.

Researchers have applied a self-learning algorithm to distinguish the almost 100 brain cancer types through their methylation pattern in a routine diagnostic setting. The method eliminates inter-pathologist variation in histopathological diagnosis and resulted in a change of diagnoses in up to 12% of prospective cases.

The tremendous success of last year’s BIO Europe Spring in Barcelona was hard to beat. But the follow-up this year in Amsterdam organised by EBD Group together with Health Holland crystallised as a worthy successor.

Domainex Ltd, a privately-owned drug discovery services company, has announced the appointment of Dr Bodo Spori as Head of Business Development for Europ.

German MYR Pharma has completed a proof of concept Phase IIb trial with its first-in-class hepatitis D entry inhibitor Myrcludex B, which is developed under the European Medicines Agency’s PRIME scheme.